Phase 2 Psoriasis Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to give their written agreement to take part after fully understanding what the trial involves
• People aged 18 to 70 years (inclusive) of any gender
• People who have been clinically diagnosed with chronic plaque psoriasis for at least 6 months before the screening visit
• People whose plaque psoriasis has been stable — meaning no major flare-ups or significant changes in appearance — for the 6 months before screening, as assessed by the study doctor
• People with moderate-to-severe psoriasis at screening, based on specific scoring measures (PASI score of 12 or higher, sPGA score of 3 or higher, and at least 10% of body surface area affected)
• People who, in the study doctor's judgement, would be a suitable candidate for light therapy or systemic (whole-body) treatment
• People who are able to become pregnant, and male participants, who agree to use highly effective contraception from the time of consent until 30 days after the last dose of study treatment

Who may not be able to join:

• People who have a form of psoriasis other than the plaque type, such as the widespread reddening type (erythrodermic), pus-filled (pustular), droplet-shaped (guttate), or a type caused by a medication
• People who have other skin conditions that the study doctor believes could interfere with assessing the results
• People who have an immune system disease (such as inflammatory bowel disease) that requires ongoing systemic (whole-body) treatment, except for standard anti-inflammatory pain medicines (NSAIDs)
• People with a history of severe allergic reactions to medications
• People who have had major surgery within 2 months before joining the trial, or who have major surgery planned during the study
• People who have had problems with drug or alcohol misuse in the 6 months before screening
• People with high blood pressure that is not well controlled at screening (above specific thresholds that the trial site can confirm)
• People who have had a heart attack, unstable chest pain, a mini-stroke or stroke, or certain heart procedures (such as a stent or bypass surgery) within 6 months before screening
• People with moderate to severe heart failure (classified as NYHA Class III or IV) at the time of screening
• People who have had a cancer or a lymph system disorder in the past 5 years — although certain skin cancers (basal cell carcinoma, localised squamous cell carcinoma) or cervical pre-cancer that were fully treated at least 1 year ago may be exceptions (confirm with trial site)
• People who have had an infection in an artificial joint, unless the artificial joint was removed or replaced at least 2 months before joining the trial
• People who have a history of certain serious or rare infections, including specific types of lung or fungal infections (confirm with trial site for specific infection types)
• People who have active or latent tuberculosis (TB), including a positive TB blood test without any symptoms
• People who have an active herpes infection (cold sores or genital herpes) at screening, or a history of a severe herpes infection such as widespread disease, brain infection, or eye involvement — or who have had shingles more than twice in 2 years
• People who have been hospitalised in the 2 months before joining for a serious bacterial, fungal, or viral infection requiring IV (intravenous) antibiotics or antivirals
• People who have received a live vaccine in the 2 months before joining, or who plan to receive one during the study
• People who have an active infection or fever requiring treatment with anti-infective medicines within 2 weeks before joining
• People with certain abnormal results on virus screening blood tests, including markers for hepatitis B, hepatitis C, HIV, or syphilis (confirm with trial site for specific markers)
• People who have previously used a TYK2 inhibitor medication (such as deucravacitinib)
• People who have used certain immune-system medications within specific timeframes before joining, including: certain psoriasis biologics (such as ustekinumab, secukinumab, ixekizumab, guselkumab, or tildrakizumab) or B-cell depleting treatments (such as rituximab) within 6 months; certain other immune modulators (such as natalizumab, alemtuzumab, abatacept, or vedolizumab) within 3 months; TNF inhibitor biologics (such as etanercept, adalimumab, infliximab, or certolizumab) within 2 months; or any other biologic psoriasis therapy within 3 months or 5 half-lives of the drug, whichever is longer
• People who have used systemic (whole-body) non-biologic psoriasis or immune-suppressing medicines within 4 weeks before joining, including medicines such as methotrexate, cyclosporine, apremilast, JAK inhibitors, oral steroids, retinoids, or a range of other immune-related treatments (confirm with trial site for the full list)
• People who have used lithium, antimalarial medicines, or injected gold preparations within 4 weeks before joining
• People who have used any herbal, plant-based, mineral, or animal-derived supplements or traditional medicines for psoriasis or immune conditions within 4 weeks before joining
• People who have received light therapy (phototherapy) for psoriasis within 4 weeks before joining
• People who have used medicated shampoos or body washes containing steroids, coal tar, salicylic acid (above 3%), or vitamin D-related ingredients within 2 weeks before joining
• People who have used any topical (applied to the skin) products that may affect psoriasis within 2 weeks before joining
• People who have taken part in another clinical trial or received any experimental treatment within 30 days or 5 half-lives of that treatment (whichever is longer) before joining, or who are currently in another trial
• People whose blood test results at screening fall outside acceptable ranges for liver function, blood cell counts, or kidney function (the trial site can provide specific values)
• People who are pregnant or breastfeeding
• People whom the study doctor considers unsuitable for any reason

Important: Always verify eligibility with the trial site directly before applying.